Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065273 · ClinicalTrials.gov registry record · Phase 3
Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay
A Phase 3 study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
NCT00065273 is a Phase 3 study that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 50 participants.
The verdict
NCT00065273, a Phase 3 study, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
Study Summary
Psychiatric drugs are often used to treat behavioral symptoms of mental retardation/developmental delay (MR/DD). These drugs can cause serious side effects. Newer drugs may have decreased side effects. This study will compare new and old drugs used to treat behavioral symptoms in people with MR/DD.
Interventions
- DRUG clozapine
- DRUG risperidone
- DRUG olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1998-07 |
| Est. Completion | 2001-06 |
| Phase | Phase 3 |
Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)305 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00065273
The ClinicalTrials.gov registry entry for NCT00065273 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which clozapine is the first listed.
NCT00065273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00065273 about?
NCT00065273 is a clinical study titled "Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay". Psychiatric drugs are often used to treat behavioral symptoms of mental retardation/developmental delay (MR/DD). These drugs can cause serious side effects. Newer drugs may have decreased side effects. This study will compare new and old drugs used to treat behavioral symptoms in people with MR/DD.
What is the current status of trial NCT00065273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 1998-07. Estimated completion is 2001-06.
What interventions are being tested in trial NCT00065273?
The interventions under investigation include: clozapine (DRUG), risperidone (DRUG), olanzapine (DRUG).
Who is sponsoring clinical trial NCT00065273?
This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.